28 Antitrust No. 1, American Bar Association
THIS ISSUE OF ANTITRUST addresses a complicated subject—the antitrust implications of the Supreme Court’s Actavis decision on reversepayment settlements. As you will see, that analysis follows several paths—practical and theoretical, specific and more general—to explore the meaning of Actavis not just for the pharmaceutical industry but also for all counsel who face rule-ofreason claims. In doing so, the magazine again succeeds in its essential purpose: to examine complex issues at the heart of our practice and present them in clear and readable form. Unfortunately, not everything we do as antitrust lawyers serves the goal of clarifying complex subject matter.